MSD’s Keytruda granted FDA extension
admin 12th April 2019 Uncategorised 0The approval is based on results from the Phase III KEYNOTE-042 trial.
More: MSD’s Keytruda granted FDA extension
Source: News
The approval is based on results from the Phase III KEYNOTE-042 trial.
More: MSD’s Keytruda granted FDA extension
Source: News
© 1994 - 2026 B.M. Pharmaceuticals